Here are four observations:
1. Ten research firms in total have issued ratings on NuVasive within the last year.
2. The highest estimate of the 10 analysts is that stock will reach $63 within the next year, while the lowest estimate sets the target price at $49.
3. Analysts have also placed the consensus earnings per share estimate for the current year at $1.13.
4. NuVasive recently reported financial results for the first quarter of 2015. NuVasive increased revenue 8.4 percent to $192.4 million in the first quarter. Also, full year 2015 GAAP earnings per share were projected at $1.12, compared to GAAP loss per share of $0.36 for 2014.
More articles on devices:
5 key trends in the U.S. orthopedic stem cell market
5 key trends in the North America internal trauma fixation device market
From the garage to a global company: 7 key notes from K2M CEO Eric Major
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
